Case · science + market · a product assessed before launch
“Enhanced bioavailability” on the label — an advantage, or a promise?
A manufacturer brought a draft capsule formula for a boswellia (frankincense) supplement and six direct questions. And the right answer isn't six separate memos. It's one coherent read of the product: which molecule actually works in the body, whether the niche is open, and how to register the product. No brands, no formulas — just the method and what moves money. Dietary supplements are not medicines; the mechanism and bioavailability figures below refer to published studies of individual substances and forms, not to claims about a specific product.
Where we started: the “general” questions were really about one specific product
The client's questions looked like general theory — “which acid is strongest”, “water-soluble form or not”. But once we matched them to the attached formula, we saw these weren't questions about chemistry in the abstract — they were about his own capsule: its delivery form and what actually sets it apart on the shelf. We don't answer questions in a vacuum — we anchor them to your actual formula. Otherwise the answers sound good and don't help you decide.
Layer 1 · which molecule actually works — and why the “hero ingredient on the label” misleads
The category's marketing hero is one “strongest” acid: in vitro it's the most potent inhibitor of a key inflammatory enzyme (IC50 ≈ 1.5 µM). But taken by mouth its blood concentration is very low — it barely absorbs. On current evidence, other acids in the complex may contribute meaningfully to the observed effect, through different molecular targets — this is a mechanistic hypothesis, not a proven clinical fact.
- The percentage of the “strong” acid on the label isn't the whole truth: the action runs across several targets.
- Chasing a single standardization number means arguing with pharmacokinetics. This is the first thing we explain before a client spends on expensive enriched raw material.
Layer 2 · form beats dose — this is where the real lever sits
The actives in this class are extremely fat-soluble (logP ≈ 7–10) and barely dissolve in water. Hence low, unpredictable absorption. Orders of magnitude, from the published literature:
- Native extract, fasted: bioavailability of the key acid is 0.24–0.35%; with fatty food it rises only to ~1.7%.
- Already-studied bioavailable forms (micellar, phospholipid) showed, in crossover studies, relative bioavailability higher by 1,720–4,291% — roughly 18–44×. These are figures for other, already-researched formulations, not for the client's product.
- A self-emulsifying form dissolved in vitro in an acidic (gastric) medium by over 90% — versus practically 0% for the native extract. High dissolution is a prerequisite for, not proof of, absorption.
How we determine this — rather than just assert it
We break the delivery form down by objective features: carrier type, behaviour of the mass in acidic and intestinal media, droplet size on emulsification, the share of active substance per dose, dependence on taking it with food. By these features the form maps to one of the classes of bioavailable technologies — and it becomes clear whether there's real “enhanced bioavailability” behind the word on the label.
Layer 3 · the hard truth: “bioavailability” on the label ≠ proven bioavailability
For the client's specific formula there were no published clinical absorption data confirming the promised uplift. The assessment is mechanistic — by the class of delivery technology and by analogy, not by a direct study of that exact formula. We said it plainly: the strongest move is to run and publish your own pharmacokinetic study of your formula; until that exists, “enhanced bioavailability” is a claim, not a proven advantage.
An external confirmation of the conclusion
We additionally cross-checked the key conclusion against an independent third-party analysis of the same product concept for another market, done several years earlier. It reached exactly the same point: the technology is claimed, but there's no clinical confirmation of that specific formulation. Two independent analyses landed on the same point — that carries more weight than any single opinion.
Layer 4 · the market: who already does this — and where it's empty
From here the report leaves the lab for the shelf. We built a market map on two levels:
- Global level — more than ten players: ingredient suppliers with advanced forms and finished reference products, down to specific technologies and evidence-base benchmark brands.
- Local level — a full sweep of the local pharmacy shelf and key marketplaces: what's actually available to the buyer here and now.
A lesson worth more than any single number
In the full report the players are named, and each niche is scored by parameters — form, bioavailability, permitted claims, saturation. And here's what matters more than any single figure: in saturated markets mono-products sell weakly — combination formulas do noticeably better, and even strong brands reach volume slowly and with serious spend on promotion. That directly shapes the choice of product form.
Layer 5 · registration: so the report ends with a plan, not just science
The last layer is getting to legal market status. The report covers: which registration to obtain and which markets it covers; which claims are allowed for a supplement and which are prohibited (you can't promise it “treats” or “relieves pain”); which dose limits apply to the active components and how to bring them within the rules so the product isn't rejected at registration. The buyer gets not just science, but a go-to-market checklist.
What's in the full report on your product
The report on a specific formula assembles the six layers into one document you can decide an investment on:
- Six concrete questions, worked through: the molecule, solubility, absorption, your delivery form, global manufacturers, the potential of combination formulas.
- A source appendix — peer-reviewed literature, every reference carrying a PMID / DOI and a primary-source verification status. Nothing is passed off as confirmed without a check: where certainty is lacking, it's flagged.
- A market map — global and local, with named players and niches scored by price, form, claims and saturation.
- An assessment of your delivery form — by objective features, mapped to a class of bioavailable technologies, with a conclusion on what it delivers versus ordinary capsules.
- A regulatory checklist — registration path, permitted claims, dose limits.
- A cross-check — key conclusions verified against independent third-party analyses of your concept, where they exist.
Who it's for
For supplement manufacturers deciding whether to launch a product, in what form, under which claims and into which market — and who want to settle it on paper, before spending on production, registration and advertising. Cost and timelines — on request, scoped to your product.
Why this sits on an engineering bureau's site
Stage 0 — research before the money
The plant and production are the bottom of the funnel. First we answer whether the product has a real, defensible advantage and whether the niche is open — and only then engineering. Next comes either the full pharma/supplement-engineering route (concept, URS, dossier, CQV) or the honest answer “not yet” or “prove demand first”.
Want this kind of read for your product?
Message on Telegram — we'll show the method on your product and scope the report to your formula, market and claims.
This report is informational and market-analytical and is not investment advice. Dietary supplements are not medicines; the mechanism and bioavailability figures shown refer to published studies of individual substances and forms and are not a claim about a product's therapeutic properties. Decisions on use, dosing and registration are made by qualified specialists.